



Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference

Nov 13 2018, 8:45 AM EST

Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights

Nov 9 2018, 4:20 PM EST

Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector

Nov 5 2018, 7:00 AM EST

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	385.95m
Last Price	\$8.05
52-Week	\$6.94 - \$22.00

11/15/2018 04:00 PM EST

Investor Relations

Christine Silverstein
Senior Vice President, Finance & Investor Relations
T: +1 (646) 813-4707
csilverstein@abeonatherapeutics.com

Management Team

Carsten Thiel, PhD

Chief Executive Officer

Timothy J. Miller, PhD

President & Chief Scientific Officer

Max Colao

Chief Commercial Officer

João Siffert, MD

Executive Vice President, Head of Research & Development and Chief Medical Officer

Stephen B. Thompson

Chief Accounting Officer

Kaye Spratt, PhD

Senior Vice President, Regulatory Affairs

Juan Ruiz, MD, PhD

Head of European Medical Affairs

Christine Silverstein

Senior Vice President, Finance & Investor Relations

Neena Patil

Senior Vice President, General Counsel and Corporate Secretary

Jay Bircher

Senior Vice President, Quality & Technical Operations

Abeona Therapeutics, Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.